fluorobenzenes has been researched along with Proteinuria in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (57.14) | 29.6817 |
| 2010's | 9 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anzalone, DA; Cain, VA; Cressman, MD; de Zeeuw, D; Heerspink, HJ; Molitoris, BA; Monyak, JT; Parving, HH; Remuzzi, G; Sowers, JR; Vidt, DG | 1 |
| Brinkkoetter, PT; Cormack-Aboud, FC; Durvasula, RV; Pippin, JW; Shankland, SJ | 1 |
| de Barros, EP; de Carvalho, JJ; dos Santos Pereira, MJ; Garcia-Pinto, AB; Machado, PY | 1 |
| Farias, RE; Ferreira, AP; Girardi, JM; Raposo, NR | 1 |
| D'Haese, P; Geryl, H; Verhulst, A | 1 |
| An, C; An, F; Dong, Z; Liu, H; Wang, Y; Wu, Y; Zhang, M; Zhang, Y | 1 |
| Chai, HT; Chang, HW; Chang, LT; Chen, YT; Chung, SY; Ko, SF; Leu, S; Lin, KC; Sun, CK; Yen, CH; Yip, HK | 1 |
| Musella, F; Paneni, F; Perrone-Filardi, P; Savarese, G; Volpe, M | 1 |
| Chang, LT; Chen, YL; Chen, YT; Hsieh, CY; Kao, YH; Leu, S; Lin, YC; Shao, PL; Sun, CK; Tsa, TH; Wallace, CG; Yen, CH; Yip, HK | 1 |
| Asai, O; Iwano, M; Matsui, M; Nakatani, K; Saito, Y; Sakan, H | 1 |
| Harris, S; Hunninghake, DB; Hutchinson, HG; Kastelein, JJ; Pears, J; Shepherd, J; Stein, EA | 1 |
| Davidson, MH | 1 |
| Cremonesi, B; Gelosa, P; Gianazza, E; Gianella, A; Guerrini, U; Nobili, E; Paoletti, R; Sironi, L; Tremoli, E | 1 |
| McKenney, JM | 1 |
| Alsheikh-Ali, AA; Ambrose, MS; Karas, RH; Kuvin, JT | 1 |
| Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
| Tiwari, A | 1 |
| Abbate, M; Banfi, C; Bellosta, S; Brioschi, M; Canavesi, M; Gelosa, P; Gianella, A; Guerrini, U; Mussoni, L; Nobili, E; Remuzzi, G; Rottoli, D; Sironi, L; Tremoli, E; Zoja, C | 1 |
| Benigni, A; Carrara, F; Cattaneo, D; Corna, D; Gaspari, F; Perico, N; Remuzzi, A; Remuzzi, G; Sangalli, F; Zoja, C | 1 |
| Bairaktari, ET; Elisaf, MS; Kostapanos, MS; Kostara, C; Lagos, KG; Milionis, HJ; Saougos, VG | 1 |
| Kawachi, H; Khadzhynov, D; Krämer, S; Kron, S; Loof, T; Martini, S; Morgera, S; Neumayer, HH; Peters, H; Shimizu, F; Wang-Rosenke, Y | 1 |
6 review(s) available for fluorobenzenes and Proteinuria
| Article | Year |
|---|---|
Effects of rosuvastatin and atorvastatin on renal function: meta-analysis.
Topics: Atorvastatin; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Proteinuria; PubMed; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2012 |
Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis.
Topics: Atorvastatin; Cardiovascular Diseases; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance.
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Biomarkers; Cholesterol, LDL; Creatine Kinase; Creatine Kinase, MM Form; Drug Approval; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Incidence; Isoenzymes; Kidney Tubules; Muscular Diseases; Product Surveillance, Postmarketing; Proteinuria; Pyridines; Pyrimidines; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides | 2004 |
Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Creatinine; Dose-Response Relationship, Drug; Drug Interactions; Fluorobenzenes; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Proteinuria; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States | 2005 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
An overview of statin-associated proteinuria.
Topics: Animals; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney; Proteins; Proteinuria; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2006 |
4 trial(s) available for fluorobenzenes and Proteinuria
| Article | Year |
|---|---|
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.
Topics: Adult; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Creatinine; Diabetes Complications; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Fluorobenzenes; Heptanoic Acids; Humans; Kidney; Lipids; North America; Proteinuria; Pyrimidines; Pyrroles; Rosuvastatin Calcium; South America; Sulfonamides | 2015 |
No evidence for statin-induced proteinuria in healthy volunteers as assessed by proteomic analysis.
Topics: Adult; Aged; Albuminuria; Cross-Over Studies; Double-Blind Method; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Proteinuria; Proteome; Proteomics; Pyrimidines; Retinol-Binding Proteins; Rosuvastatin Calcium; Sulfonamides; Two-Dimensional Difference Gel Electrophoresis | 2011 |
Safety of rosuvastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Biomarkers; Child; Cholesterol, LDL; Creatine Kinase; Dose-Response Relationship, Drug; Eye; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney; Liver; Male; Middle Aged; Muscle, Skeletal; Proteinuria; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2004 |
Dose-dependent effect of rosuvastatin treatment on urinary protein excretion.
Topics: Alpha-Globulins; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Prospective Studies; Proteinuria; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2007 |
11 other study(ies) available for fluorobenzenes and Proteinuria
| Article | Year |
|---|---|
Rosuvastatin protects against podocyte apoptosis in vitro.
Topics: Animals; Apoptosis; Cell Survival; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Knockout; Podocytes; Proteinuria; Puromycin Aminonucleoside; Pyrimidines; Recombinant Proteins; Rosuvastatin Calcium; Sulfonamides; Transduction, Genetic | 2009 |
Rosuvastatin beneficially alters the glomerular structure of kidneys from spontaneously hypertensive rats (SHRs).
Topics: Animals; Blood Chemical Analysis; Blood Pressure; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Glomerulus; Proteinuria; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosuvastatin Calcium; Sulfonamides | 2011 |
Rosuvastatin prevents proteinuria and renal inflammation in nitric oxide-deficient rats.
Topics: Animals; Blood Pressure; Drug Therapy, Combination; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukins; Kidney Diseases; Male; Nephritis; NG-Nitroarginine Methyl Ester; Nitric Oxide; Plethysmography; Proteinuria; Pyrimidines; Random Allocation; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides | 2011 |
Chronic exposure to environmental contaminant nonylphenol exacerbates adenine-induced chronic renal insufficiency: role of signaling pathways and therapeutic impact of rosuvastatin.
Topics: Adenine; Animals; Biomarkers; Blood Urea Nitrogen; Body Weight; Creatinine; Cytoprotection; Disease Models, Animal; Endothelial Cells; Environmental Pollutants; Fibrosis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Membrane Glycoproteins; Mitogen-Activated Protein Kinases; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Phenols; Protein Kinase C; Proteinuria; Pyrimidines; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; Time Factors | 2012 |
Continuing exposure to low-dose nonylphenol aggravates adenine-induced chronic renal dysfunction and role of rosuvastatin therapy.
Topics: Adenine; Animals; Apoptosis; Biomarkers; Blood Urea Nitrogen; Creatinine; Environmental Exposure; Fluorescent Antibody Technique; Fluorobenzenes; Kidney Tubules; Male; Oxidative Stress; Phenols; Proteinuria; Pyrimidines; Rats; Rats, Wistar; Reactive Oxygen Species; Renal Insufficiency, Chronic; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides | 2012 |
[Case of purpura nephritis accompanied by idiopathic cholesterol embolism].
Topics: Aged; Embolism, Cholesterol; Fluorobenzenes; Humans; IgA Vasculitis; Kidney Glomerulus; Kidney Tubules; Male; Nephritis; Prednisolone; Proteinuria; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2012 |
Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects.
Topics: Acute-Phase Proteins; Animals; Cerebral Arteries; Chemokine CCL2; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; P-Selectin; Proteinuria; Pyrimidines; Rats; Rats, Inbred SHR; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sodium Chloride, Dietary; Stroke; Sulfonamides; Transcription, Genetic; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vasculitis | 2005 |
The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.
Topics: Consumer Product Safety; Drug Evaluation; Drug Prescriptions; Fluorobenzenes; Humans; Kidney Diseases; Morbidity; Product Surveillance, Postmarketing; Proteinuria; Pyridines; Pyrimidines; Renal Insufficiency; Retrospective Studies; Rhabdomyolysis; Rosuvastatin Calcium; Sulfonamides | 2005 |
Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats.
Topics: Actins; Animals; Blood Pressure; Blotting, Western; Collagen; Disease Progression; Fibrinogen; Fibrinolysin; Fibrosis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Kidney; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Microscopy, Electron; Plasminogen Activator Inhibitor 1; Plasminogen Activators; Podocytes; Proteinuria; Pyrimidines; Rats; Rats, Inbred SHR; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides | 2007 |
Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation.
Topics: Animals; Capillaries; Capillary Permeability; Disease Models, Animal; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Glomerulus; Proteinuria; Pyrimidines; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Sulfonamides | 2007 |
Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Fluorobenzenes; Glomerulosclerosis, Focal Segmental; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Glomerulus; Male; Proteinuria; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Tetrazoles | 2008 |